Skip to Main content Skip to Navigation
New interface
Journal articles

Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Arantxa González 1 A. Mark Richards 2, 3, 4 Rudolf A de Boer 5 Thomas Thum 6, 7, 8 Henrike Arfsten 9, 10 Martin Hülsmann 9 Inês Falcao-Pires 11 Javier Díez 1, 12 Roger S.Y. Foo 2, 3 Mark Y Chan 2, 3 Alberto Aimo 13, 14 Chukwuemeka G Anene-Nzelu 2, 3, 15 Magdy Abdelhamid 16 Stamatis Adamopoulos 17 Stefan D Anker 18, 10 Yuri Belenkov 19 Tuvia Ben Gal 20 Alain Cohen-Solal 21 Michael Böhm 22 Ovidiu Chioncel 23 Victoria Delgado 24 Michele Emdin 13, 25 Ewa A Jankowska 26 Finn Gustafsson 27 Loreena Hill 28 Tiny Jaarsma 29 James L Januzzi 30, 31 Pardeep S Jhund 32 Yuri Lopatin 33 Lars H Lund 34, 35 Marco Metra 36 Davor Milicic 37 Brenda Moura 38, 39 Christian Mueller 40 Wilfried Mullens 41 Julio Núñez 42, 43 Massimo F Piepoli 44 Amina Rakisheva 45 Arsen D Ristic 46 Patrick Rossignol 47, 48, 49, 50 Gianluigi Savarese 51 Carlo G Tocchetti 52 Sophie van Linthout 10, 53 Maurizio Volterrani 54 Petar Seferovic 55, 56 Giuseppe Rosano 57 Andrew J.S. Coats 58 Antoni Bayés-Genís 42, 59, 60 
Abstract : Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.
Complete list of metadata
Contributor : Erwan BOZEC Connect in order to contact the contributor
Submitted on : Thursday, October 6, 2022 - 4:29:03 PM
Last modification on : Friday, October 7, 2022 - 11:40:55 AM


Cardiac remodeling part 1.pdf
Files produced by the author(s)




Arantxa González, A. Mark Richards, Rudolf A de Boer, Thomas Thum, Henrike Arfsten, et al.. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24 (6), pp.927-943. ⟨10.1002/ejhf.2493⟩. ⟨hal-03800912⟩



Record views


Files downloads